PDCD1 and hepatocellular carcinoma: Triple therapy significantly improves survival outcomes in high-risk advanced hepatocellular carcinoma (aHCC) patients with an acceptable safety profile compared with tyrosine kinase inhibitor (TKI) plus programmed cell death protein-1 inhibitors (PD-1 inhibitors).